Clinical Trial Detail

NCT ID NCT02000947
Title A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors MedImmune LLC
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Tremelimumab

Age Groups: adult

No variant requirements are available.